
|Articles|March 5, 2015
Clonal Heterogeneity in Urothelial Cancer
Author(s)Bishoy Faltas, MD
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discusses clonal heterogeneity in platinum-resistant metastatic urothelial cancer.
Advertisement
Clinical Pearls
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discussesclonal heterogeneity in platinum-resistant metastatic urothelial cancer.
- This study found a significant degree of both inter- and intra-patient heterogeneity.
- There were differences in the patterns of evolution of molecular alterations in these samples.
- Subclonal mutations went on to be enriched in and constitute most mutations in metastatic samples.
- Mutations in primary samples were identified that were not enriched in metastatic samples.
- It was found that the metastatic samples continued to change even after evolving from the primary tumor samples.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
5









































